This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07430917 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Abrexa Pharmaceuticals, Inc. |
| Enrollment | 196 participants |
| Design | Interventional, Randomized, Sequential, Masking: Quadruple |
| Conditions | Acute Ischemic Stroke |
| Interventions | J147 Emulsion for Injection; Placebo |
| Start | Jul 22, 2026 |
| Primary completion | Mar 1, 2028 |
| Study completion | Jul 1, 2028 |
| Results posted | Not yet |
| Registry last updated | Aug 24, 2026 |
| Collaborators | IQVIA RDS Inc. |
Compounds on this site that cite this trial
What the registry says the trial is about
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 after therapy to clear the blood clot to those who don't receive J147. Participants will be asked to undergo a series of three to four magnetic resonance imaging (MRI) brain scans, and blood samples will be collected at several time points. Participants will also be evaluated to measure several aspects of brain function.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Safety of J147 Emulsion for Injection (J147) when administered with endovascular therapy in acute ischemic stroke patients. | From enrollment to end of study at 90 days. |
4 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
